Drug intelligence / Profile preview

GSK961081 + propranolol

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Inhalation

Overview

GSK961081 + propranolol is an investigational combination in which **GSK961081**, a bi-functional molecule (MABA) that combines muscarinic antagonist and β2 adrenergic agonist activities, is co-administered with **propranolol**, a non-selective beta-adrenergic antagonist. GSK961081 acts via bronchodilation through both muscarinic receptor blockade and β2 adrenoceptor agonism; propranolol blocks β-receptors (including β2), allowing study of the contribution of the muscarinic antagonist component alone. This combination has been studied in healthy volunteers to explore the pharmacology and contribution of each pharmacophore for respiratory indications such as COPD.

Other names: GSK961081 + propranolol

Targets

ADRB2 (β2)ADRB3 (β3)ADRB1 (β1)CHRM3 (M3)

Beyond the preview

Go deeper on GSK961081 + propranolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK961081 + propranolol.

Explore the full profile